L3VLUP
ProSign in

COO · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

COOLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • COO
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterCOOLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 2022none listed holders, n.a.24 holders, $35.3bn
Q2 2022none listed holders, n.a.33 holders, $42.7bn
Q3 2022none listed holders, n.a.31 holders, $43.4bn
Q4 2022none listed holders, n.a.31 holders, $46.6bn
Q1 2023none listed holders, n.a.33 holders, $44.3bn
Q2 2023none listed holders, n.a.37 holders, $59.6bn
Q3 2023none listed holders, n.a.44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 202421 holders, $3.0bn41 holders, $95.3bn
Q2 202419 holders, $2.5bn43 holders, $110bn
Q3 202419 holders, $3.3bn45 holders, $107bn
Q4 202416 holders, $2.9bn46 holders, $93.9bn
Q1 202519 holders, $3.2bn42 holders, $98.4bn
Q2 202521 holders, $3.0bn43 holders, $93.2bn
Q3 202516 holders, $3.2bn39 holders, $86.7bn
Q4 202517 holders, $3.4bn41 holders, $123bn
Q1 202613 holders, $2.6bn39 holders, $106bn
Q2 202619 holders, $2.6bn44 holders, $132bn
COO

Cooper Cos Inc

Holders
19
Reported value
$2.6bn
Buyers
24
Sellers
9

Breadth +15 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only COO (4)

Caxton Associates LLP, Jana Partners, Moore Capital Management LP, Winton Group Ltd

Only LLY (29)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Discovery Capital Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Glenview Capital Management LLC, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, Squarepoint Ops LLC, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →